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A B S T R A C T
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying
tissue, or both. Negative pressure wound therapy (NPWT) is a treatment option for pressure ulcers; a clear, current overview of the
evidence is required to facilitate decision-making regarding its use.
Objectives
To assess the effects of negative pressure wound therapy for treating pressure ulcers in any care setting.
Search methods
For this review, we searched the following databases in May 2015: the Cochrane Wounds Group Specialised Register; The Cochrane
Central Register of Controlled Trials (CENTRAL; The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other
Non-Indexed Citations); Ovid EMBASE; and EBSCOCINAHL. There were no restrictions based on language or date of publication.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) comparing the effects of NPWT with alternative treatments or different
types of NPWT in the treatment of pressure ulcers (stage II or above).
Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction.
Main results
The review contains four studies with a total of 149 participants. Two studies compared NPWT with dressings; one study compared
NPWT with a series of gel treatments and one study compared NPWT with ’moist wound healing’. One study had a 24-week follow-
up period, and two had a six-week follow-up period, the follow-up time was unclear for one study. Three of the four included studies
were deemed to be at a high risk of bias from one or more ’Risk of bias’ domains and all evidence was deemed to be of very low quality.
Only one study reported usable primary outcome data (complete wound healing), but this had only 12 participants and there were very
few events (only one participant healed in the study). There was little other useful data available from the included studies on positive
outcomes such as wound healing or negative outcomes such as adverse events.
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Authors’ conclusions
There is currently no rigorous RCT evidence available regarding the effects of NPWT compared with alternatives for the treatment
of pressure ulcers. High uncertainty remains about the potential benefits or harms, or both, of using this treatment for pressure ulcer
management.
P L A I N L A N G U A G E S U M M A R Y
Negative pressure wound therapy for treating pressure ulcers
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are areas of injury to the skin, the tissue that lies
underneath, or both. Pressure ulcers can be painful, may become infected, and affect people’s quality of life. People at risk of developing
pressure ulcers include those with spinal cord injuries, and those who are immobile or who have limited mobility.
In 2004 the total annual cost of treating pressure ulcers in the UK was estimated as being GBP 1.4 to 2.1 billion, which was equivalent
to 4% of the total National Health Service expenditure. People with pressure ulcers stay longer when admitted to hospital, and this
increases hospital costs. Figures from the USA for 2006 suggest that half a million hospital stays had ’pressure ulcer’ noted as a diagnosis;
the total hospital costs of these stays was USD 11 billion.
There is a wide variety of treatment options available for pressure ulcers, such as dressings, creams, redistribution of pressure, and
negative pressure wound therapy (NPWT). NPWT is a technology that is used widely and is promoted for use on wounds, including
pressure ulcers. In NPWT a machine which exerts carefully controlled suction (negative pressure) is attached to a wound dressing that
covers the pressure ulcer. This sucks any wound and tissue fluid away from the treated area into a canister. The researchers tried to
discover whether NPWT works well as a treatment for pressure ulcers.
What we found
We searched the medical literature up to May 2015 for robust medical studies (randomised controlled studies) that compared NPWT
with other treatments for pressure ulcers. We identified four studies involving a total of 149 participants. Two studies compared NPWT
with dressings, one compared NPWT with a series of topical treatments and one study compared it with what was described only as
’moist wound healing’. The trials were small, and poorly described, of fairly short or unclear duration, and contained little in the way
of useful data.
As a result of the limited amount of research evidence available, we were not able to draw any conclusions regarding the potential value
(or harm) of NPWT as a treatment for pressure ulcers. More, better quality research is needed if this is an important and relevant
question for decision makers.
This plain language summary is up-to-date as of May 2015.
B A C K G R O U N D
Description of the condition
Pressure ulcers, also known as bedsores, decubitus ulcers and pres-
sure injuries, are localised areas of injury to the skin or the under-
lying tissue, or both. They often occur in areas with a bony promi-
nence such as the sacrum (base of the spine) and heel (Vanderwee
2007), and are caused by external forces such as pressure, or shear,
or a combination of both (EPUAP-NPUAP 2009).
Populations at risk of pressure ulceration include those with spinal
cord injuries (Gefen 2014), and those immobilised or with limited
mobility such as elderly people and people with acute or chronic
conditions thatmight limitmovement or bodily sensation, or both
(Allman 1997; Berlowitz 1990; Berlowitz 1997; Bergstrom 1998;
Brandeis 1994). Incontinence can also increase risk of ulceration
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by producing a detrimental environment for the skin (Brandeis
1994). Impaired nutritional status may also increase risk (Allman
1997; Donini 2005), however, there is currently limited evidence
for the effectiveness of nutritional intake interventions for pre-
venting or treating pressure ulcers (Langer 2003; Smith 2013).
Mobility produces relief from pressure within the body through
regular, often sub-conscious, shifts in positions when sitting or
lying. These movements, triggered by a reduction in oxygen lev-
els at pressure points and possible discomfort, distribute pressure
from contact at the surface, thus reducing the compression of soft
tissue against bone (Gebhardt 2002). Populations with limited
autonomous movement or conditions that dull body sensation,
or both (as described above), are at risk of failing to achieve ade-
quate pressure relief. Prolonged exposure of an area of the body to
pressure or compression can interrupt the local blood circulation
and trigger a cascade of biochemical changes that may lead to tis-
sue damage and ulceration. Immobility can also lead to increased
damage from shear and friction, for example, when people are
pulled into position in chairs and beds.
Pressure ulcers vary in severity. One of the most widely recognised
systems for categorising pressure ulcers is that of theNational Pres-
sure Ulcer Advisory Panel which is summarised below (NPUAP
2009).
Category/Stage I - non-blanchable erythema: “Intact skin with
non-blanchable redness of a localized area usually over a bony
prominence. Darkly pigmented skin may not have visible blanch-
ing; its colour may differ from the surrounding area. The area may
be painful, firm, soft, warmer or cooler as compared to adjacent
tissue. Category I may be difficult to detect in individuals with
dark skin tones. May indicate ”at risk“ persons.”
Category/Stage II - partial thickness: “Partial thickness loss of
dermis presenting as a shallow open ulcer with a red pink wound
bed, without slough. May also present as an intact or open/rup-
tured serum-filled or sero-sanguinous filled blister. Presents as a
shiny or dry shallow ulcer without slough or bruising (bruising
indicates deep tissue injury). This category should not be used to
describe skin tears, tape burns, incontinence associated dermatitis,
maceration or excoriation.”
Category/Stage III - full thickness skin loss: “Full thickness tis-
sue loss. Subcutaneous fatmay be visible but bone, tendon ormus-
cle are not exposed. Slough may be present but does not obscure
the depth of tissue loss. May include undermining and tunnelling.
The depth of a Category/Stage III pressure ulcer varies by anatom-
ical location. The bridge of the nose, ear, occiput and malleolus
do not have (adipose) subcutaneous tissue and Category/Stage III
ulcers can be shallow. In contrast, areas of significant adiposity can
develop extremely deep Category/Stage III pressure ulcers. Bone/
tendon is not visible or directly palpable.”
Category/Stage IV - full thickness tissue loss: “Full thickness
tissue loss with exposed bone, tendon or muscle. Slough or eschar
may be present. Often includes undermining and tunnelling. The
depth of a Category/Stage IV pressure ulcer varies by anatomical
location. The bridge of the nose, ear, occiput and malleolus do
not have (adipose) subcutaneous tissue and these ulcers can be
shallow. Category/Stage IV ulcers can extend into muscle and/or
supporting structures (e.g., fascia, tendon or joint capsule) making
osteomyelitis or osteitis likely to occur. Exposed bone/muscle is
visible or directly palpable.”
Pressure ulcers are relatively common, but complex, wounds.
Prevalence estimates vary according to the population being as-
sessed, the data collection methods used and decisions about
whether or not stage I pressure ulcers should be included (since
there is no open wound at this stage but evidence of possible tissue
damage). A large survey of hospital patients undertaken in several
European countries returned a pressure ulcer prevalence (stage II
and above) of 10.5% (Vanderwee 2007). In 2009, a USA estimate
for pressure ulcer prevalence (stage II and above) across acute-care,
long-term care and rehabilitation settings was 9%, with prevalence
highest in long-term acute-care settings (26%; VanGilder 2009).
In the UK, national pressure ulcer data are collected across com-
munity and acute settings - although data collection is not yet
universal - as part of the National Health Service (NHS) Safety
Thermometer initiative (Power 2012). In January 2014, 5% of
patients across these settings were estimated to have a pressure ul-
cer (National Safety Thermometer Data 2014).
We note that all of the prevalence figures quoted above are for pop-
ulations currently receiving medical care. The point prevalence of
pressure ulceration in the total adult population was recently es-
timated using a cross-sectional survey undertaken in Leeds, UK.
Of the total adult population of 751,485 the point prevalence
of pressure ulceration per 1000 was 0.31 (Hall 2014). UK pres-
sure ulcer prevalence estimates specifically for community settings
have reported rates of 0.77 per 1000 adults in a UK urban area
(Stevenson 2013).
Pressure ulcers have a large impact on those affected; the ulcers can
be painful, and may become seriously infected or malodorous. It
has been shown that - after adjustment for age, sex and co-mor-
bidities - people with pressure ulcers have a lower health-related
quality of life than those without pressure ulcers (Essex 2009). The
financial cost of treating ulcers in the UK was recently estimated
as being between GBP 1214 for a stage I ulcer, to GBP 14,108
for a stage IV ulcer (Dealey 2012). In 2004 the total annual cost
of treating pressure ulcers in the UK was estimated as being GBP
1.4 to 2.1 billion, which was equivalent to 4% of the total NHS
expenditure (Bennett 2004). Pressure ulcers have been shown to
increase length of hospital stay, readmission and mortality rates
(Lyder 2012), and to add considerably to the cost of an episode of
hospital care (Chan 2013). Figures from the USA suggest that for
half a million hospital stays in 2006 ’pressure ulcer’ was noted as a
diagnosis; for adults, the total hospital costs of these stays wasUSD
11 billion (Russo 2008). Costs to the Australian healthcare system
for treating pressure ulceration have been estimated at AUD 285
million per annum (Graves 2005).
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Description of the intervention
Negative pressure wound therapy (NPWT) is a technology that is
currently used widely in wound care and is promoted for use on
complex wounds (e.g. Guy 2012). NPWT involves the applica-
tion of a wound dressing through which a negative pressure (or
vacuum) is applied, often with the wound and tissue fluid drawn
away from the area being collected in a canister. The interven-
tion was developed in the 1990s, and the uptake of NPWT in
the healthcare systems of developed countries has been dramatic.
A US Department of Health report estimated that between 2001
and 2007, Medicare payments for NPWT pumps and associated
equipment increased from USD 24 million to USD 164 million
(an increase of almost 600%; Department of Health and Human
Services 2009). Initially only one NPWT manufacturer supplied
NPWT machines (the VAC system: Kinetic Concepts Inc (KCI),
San Antonio, Texas), however, as the NPWT market has grown,
a number of different commercial NPWT systems have been de-
veloped, with machines becoming smaller and more portable. In-
deed, the most recent introduction to the market is a single use, or
’disposable’, negative pressure product. Ad hoc, non-commercial,
negative pressure devices are also used, especially in resource-poor
settings. These devices tend to use simple wound dressings, such
as gauze, or transparent occlusive (non-permeable) dressings, with
negative pressure generated in hospital by vacuum suction pumps.
A number of different healthcare professionals prescribe and apply
NPWT, and it is now used both in secondary and primary (com-
munity) care, particularly following the introduction of ambula-
tory systems, and prophylactically, to prevent surgical site infec-
tion. Whilst the NPWT systems outlined above differ in a num-
ber of respects - such as type of pressure (constant or cyclical) ap-
plied to the wound, the material in contact with the surface of
the wound and also the type of dressing used - the principle of
applying a negative pressure to the wound in a closed environment
is the same for all products.
How the intervention might work
NPWTcan collect high volumes of wound exudate, somay reduce
the frequency of dressing changes, and subsequent exposure of the
wound to the environment. This collection of exudate ostensibly
assists in the management of anatomically-challenging wounds,
keeps wounds clean, and reduces wound odour. Manufacturers,
however, also suggest that the application of negative pressure (suc-
tion) to the wound actually promotes healing by drawing together
the wound edges, increasing perfusion (oxygenated blood in the
tissues) and removing infectious material and exudate (Kinetic
Concepts Inc 2012).
Potential negative consequences of NPWT include wound macer-
ation (softening due to exposure to liquid), and retention of dress-
ing materials that may cause wound infection, as well as other in-
juries (FDA 2011). NPWT devices are usually worn continually
by patients during treatment. They can interfere with mobility,
and, anecdotally, are often noisy, which prevents some patients
from sleeping.
Why it is important to do this review
Given its widespread use, it is important to assess the current
evidence regarding the clinical and cost effectiveness of NPWT.
Previous review work has found little evidence about the effects of
NPWT on severe pressure ulcers (Soares 2013). UK pressure ulcer
guidelines (for both prevention and management) advise “Do not
routinely offer adults negative pressure wound therapy to treat
a pressure ulcer, unless it is necessary to reduce the number of
dressing changes (for example, in a wound with a large amount of
exudate)” (NICE 2014). The guidelines also highlight the need for
further research, noting that there would be “benefits to patients
and the NHS in establishing whether negative pressure wound
therapy improves the healing of pressure ulcers.” The production
of a robust and updated systematic review can contribute to this
aim by identifying, appraising and synthesising the evidence base
to inform decision makers and possibly guide future research.
O B J E C T I V E S
To assess the effects of negative pressure wound therapy for treating
pressure ulcers in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs), including cluster RCTs, irrespective of the language
of report. Cross-over trials would be included only if they reported
outcome data at end of the first treatment period, before cross-
over. Studies using quasi-randomisation were excluded.
Types of participants
We included studies recruiting adults with a pressure ulcer (cate-
gory II or above), managed in any care setting. We excluded trials
of participants with category I ulcers. We accepted study authors’
definitions of what they classed as category II or above, unless it
was clear that wounds with unbroken skin were included. Studies
that recruited participants with category II or higher pressure ul-
cers alongside people with other types of wounds were included if
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the results for people with relevant pressure ulcers were presented
separately (or were available from the study authors).
Types of interventions
The primary intervention of interest was negative pressure wound
therapy (NPWT), both commercial and non-commercial treat-
ments. We included any RCT in which the NPWT during the
treatment period was the only systematic difference between treat-
ment groups. We anticipated likely comparisons would include
use of NPWT during the care pathway compared with no use of
NPWT, or comparison of different types/brands of NPWT used
during the care pathway.
Types of outcome measures
We list primary and secondary outcomes below. If a study was
apparently eligible (i.e. correct study design, population and in-
tervention/comparator), but did not report a listed outcome, we
contacted the study authors where possible to establish whether
an outcome of interest here was measured, but not reported.
We report outcome measures at the latest time point available
for a study (assumed to be length of follow-up if not specified)
and the time point specified in the methods as being of primary
interest (if this was different from latest time point available). For
all outcomes we categorise outcomes from:
• under a week to eight weeks as short-term;
• over eight weeks to 26 weeks as medium-term; and
• over 26 weeks as long-term.
Primary outcomes
The primary outcomes for this review were complete wound heal-
ing and adverse events.
Complete wound healing
For this review we regarded the following as providing the most
relevant and rigorous measures of wound healing:
• time to complete wound healing: we recorded whether this
had been correctly analysed using censored data and with
adjustment for prognostic covariates such as baseline size;
• the proportion of ulcers healed (frequency of complete
healing).
Where both the outcomes above were reported, we present all data
in a summary outcome table for reference. Where equal amounts
of information were available, we anticipated focusing on time to
healing as the key outcome measure. We accepted authors’ defini-
tions of what constituted a healed wound.
Adverse events (generic)
Reported data were extracted on adverse events classed as ’seri-
ous adverse events’ and ’non-serious adverse events’ where a clear
methodology for the collection of adverse event data was provided.
This methodology needed to make it clear whether events were
reported at the participant level or, where multiple events/person
were reported, that an appropriate adjustment had been made for
data clustering. Individual types of adverse events such as pain or
infection that require specific assessment were not extracted under
this outcome - rather this is the assessment of any event classed as
adverse by the patient and or health professional during the trial.
Secondary outcomes
• Change (and rate of change) in wound size, with
adjustment for baseline size: we contacted study authors to
request adjusted means when these were not presented. Where
change or rate of change in wound size was reported without
adjustment for baseline size, we documented use of the outcome
in the study, but did not summarize the data in the narrative or
use them in any meta-analysis.
• Participant health-related quality of life/health status:
measured using a standardised generic questionnaire such as EQ-
5D, SF-36, SF-12 or SF-6 or wound-specific questionnaires such
as the Cardiff wound impact schedule. We did not include ad
hoc measures of quality of life that were not likely to be validated
and would not be common to multiple trials.
• Wound infection: as defined by author.
• Mean pain scores: (including pain at dressing change) we
included this information only where the data were reported as
either a presence or absence of pain, or as a continuous outcome
using a validated scale such as a visual analogue scale (VAS).
• Resource use: including measurements of resource use such
as number of dressing changes, nurse visits, length of hospital
stay, re-admission and re-operation/intervention.
• Costs: any costs applied to resource use.
• Wound recurrence: as defined by study author.
Search methods for identification of studies
Electronic searches
In May 2015 we searched the following electronic databases to
retrieve reports of potentially relevant RCTs.
• The Cochrane Wounds Group Specialised Register
(searched 19 May 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL; The Cochrane Library 2015, Issue 4);
• Ovid MEDLINE (1946 to 18 May 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations 18 May 2015);
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• Ovid EMBASE (1974 to 18 May 2015);
• EBSCO CINAHL (1982 to 18 May 2015).
The Cochrane Central Register of Controlled Trials (CENTRAL)
search string is given below:
#1 MeSH descriptor: [Negative-Pressure Wound Therapy] ex-
plode all trees
#2 MeSH descriptor: [Suction] explode all trees
#3 MeSH descriptor: [Vacuum] explode all trees
#4 (“negative pressure” or negative-pressure or TNP or NPWT):
ti,ab,kw
#5 (sub-atmospheric or subatmospheric):ti,ab,kw
#6 ((seal* next surface*) or (seal* next aspirat*)):ti,ab,kw
#7 (wound near/3 suction*):ti,ab,kw
#8 (wound near/3 drainage):ti,ab,kw
#9 (foam next suction) or (suction next dressing*):ti,ab,kw
#10 (vacuum assisted closure or VAC):ti,ab,kw
#11 (vacuumnext therapy) or (vacuumnext dressing*) or (vacuum
next seal*) or (vacuum next assist*) or (vacuum near closure) or
(vacuum next compression) or (vacuum next pack*) or (vacuum
next drainage) or (suction* adj drainage):ti,ab,kw
#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11)
#13 MeSH descriptor: [Pressure Ulcer] explode all trees
#14 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#15 (decubitus next (ulcer* or sore*)):ti,ab,kw
#16 ((bed next sore*) or bedsore*):ti,ab,kw
#17 #13 or #14 or #15 or #16
#18 #12 and #17
We combined the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity- and precision-maximising version
(2008 revision; Lefebvre 2011). We combined the EMBASE
search with the Ovid EMBASE filter developed by the UK
Cochrane Centre (Lefebvre 2011). We combined the CINAHL
searches with the trial filters developed by the Scottish Intercolle-
giate Guidelines Network (SIGN 2011). The search strategies are
detailed in Appendix 1. There were no restrictions with respect to
language, date of publication or study setting.
We also searched the following clinical trials registries:
• Clinical Trials.gov (www.clinicaltrial.gov)
• WHO International Clinical Trials Registry Platform
(ICTR) (http://apps.who.int/trialsearch/Default.aspx)
• The EU Clinical Trials Register
(www.clinicatrialsregister.eu)
Searching other resources
We contacted corresponding authors and the manufacturers and
distributors of NPWT. We tried to identify other potentially eli-
gible trials or ancillary publications by searching the reference lists
of retrieved included trials as well as relevant systematic reviews,
meta-analyses, and health technology assessment reports.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
of the citations retrieved by the searches for relevance. After this
initial assessment, we obtained full text copies of all studies felt to
be potentially relevant. Two review authors independently checked
the full papers for eligibility; disagreements were resolved by dis-
cussion and, where required, the input of a third review author.We
recorded all reasons for the exclusion of studies for which we had
obtained full copies of the text. We have completed a PRISMA
flowchart to summarize this process (Figure 1; Liberati 2009).
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Figure 1. Study flow diagram.
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Where required we would obtain all relevant publications when
studies were reported more than once. Whilst the study was in-
cluded only once in the review, all reports were examined to ensure
the maximal extraction of relevant data.
Data extraction and management
We extracted and summarize details of the eligible studies. Two re-
view authors extracted data independently and resolved disagree-
ments by discussion, drawing on a third review author where
required. Where data were missing from reports, we attempted
to contact the study authors to obtain this information. Had a
study with more than two intervention arms been included, we
would have extracted only those data from intervention and con-
trol groups that met the eligibility criteria.
We extracted the following data where possible, by treatment
group, for the pre-specified interventions and outcomes in this
review. Outcome data were collected for relevant time points as
described in Types of outcome measures.
• Country of origin
• Type of wound and surgery
• Unit of randomisation (per patient) - single wound or
multiple wounds on the same patient
• Unit of analysis
• Trial design e.g. parallel cluster
• Care setting
• Number of participants randomised to each trial arm
• Eligibility criteria and key baseline participant data
• Details of treatment regimen received by each group
• Duration of treatment
• Details of any co-interventions
• Primary and secondary outcome(s) (with definitions)
• Outcome data for primary and secondary outcomes (by
group)
• Duration of follow-up
• Number of withdrawals (by group)
• Publication status of study; and
• Source of funding for trial.
Assessment of risk of bias in included studies
Two review authors independently assessed included studies using
the Cochrane Collaboration tool for assessing risk of bias (Higgins
2011a). This tool addresses six specific domains: sequence genera-
tion, allocation concealment, blinding, incomplete data, selective
outcome reporting and other issues. In this review we recorded
issues with unit of analysis, for example where a cluster trial has
been undertaken but analysed at the individual level in the study
report (Appendix 2). We assessed blinding and completeness of
outcome data for each of the review outcomes separately. We note
that, since wound healing is a subjective outcome, it can be at high
risk of measurement bias when outcome assessment is not blinded.
We present our assessment of risk of bias using two ’Risk of bias’
summary figures; one is a summary of bias for each item across
all studies, and the second shows a cross-tabulation of each trial
by all of the ’Risk of bias’ items. We planned to class studies with
an assessment of high risk of bias for the randomisation sequence
domain or the allocation concealment domain, or both, to be at
a high risk of selection bias; those at a high risk of bias for the
blinded outcome assessment domain (for a specified outcome) as
being at a high risk of detection bias, and those with a high risk of
bias for the intention-to-treatment domain as being at a high risk
of attrition bias (for a specified outcome).
For trials using cluster randomisation, we assessed the risk of bias
considering recruitment bias, baseline imbalance, loss of clusters,
incorrect analysis and comparability with individually randomised
trials (Higgins 2011b; Appendix 3).
Measures of treatment effect
For dichotomous outcomes we calculated the risk ratio (RR) with
95% confidence intervals (CI). For continuously distributed out-
come data we used the mean difference (MD) with 95% CIs,
for trials that used the same assessment scale. If trials used differ-
ent assessment scales, we used the standardised mean difference
(SMD) with 95% CIs. We only considered mean or median time
to healing without survival analysis as a valid outcome if reports
specified that all wounds healed (i.e. if the trial authors regarded
time to healing as a continuous measure, as there is no censoring).
Time-to-event data (e.g. time-to-complete wound healing), were
reported as hazard ratios (HR) where possible in accordance with
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011). If studies reporting time-to-
event data (e.g. time to healing) did not report a hazard ratio, then,
where feasible, we planned to estimate this using other reported
outcomes, such as the numbers of events, through the application
of available statistical methods (Parmar 1998).
Unit of analysis issues
Where studies randomised at the participant level and measured
outcomes at the wound level, for example for wound healing, and
the number of wounds appeared to be equal to the number of
participants, we treated the participant as the unit of analysis.
We had anticipated a possible unit of analysis issue if individual
participants with multiple wounds were randomised, the allocated
treatment used on the multiple wounds per participant (or per-
haps only on some participants) and then data were presented and
analysed by wound not person. This is a type of clustered data
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and presents a unit of analysis error which inflates precision. In
cases where included studies contained some or all clustered data
we planned to report this alongside whether data had been (incor-
rectly) treated as independent. We recorded this as part of the risk
of bias assessment. We did not plan to undertake further calcula-
tion to adjust for clustering.
We also planned to record when randomisation and allocation had
been undertaken at the wound level - that is a split-site or split-
body design, and assess whether the correct paired analysis had
been undertaken in the study, issues would have been recorded in
the risk of bias section.
Dealing with missing data
It is common to have data missing from trial reports. Exclud-
ing participants post-randomisation from the analysis, or ignoring
those participants who are lost to follow-up compromises the ran-
domisation, and potentially introduces bias into the trial. Where
there were data missing that we thought should be included in
the analyses, we contacted the relevant study authors to enquire
whether these data were available.
Where data for ’proportion of wounds healed’ remained missing,
we assumed that if randomised participants were not included in
an analysis, theirwounddidnot heal (i.e. theywould be considered
in the denominator but not the numerator).
In a time-to-healing analysis using survival analysismethods, drop-
outs should be accounted for as censored data, so we took no
action regarding missing data.
For continuous variables, for example length of hospital stay, and
for all secondary outcomes, we presented the data available from
the study reports/study authors anddidnot plan to imputemissing
data. We calculated missing measures of variance where possible.
If calculation was not possible, we contacted the study authors.
Where these measures of variation were not available the study was
excluded from any relevant meta-analyses that were conducted.
Assessment of heterogeneity
Assessment of heterogeneity can be a complex, multi-faceted pro-
cess. Where assessment of heterogeneity was required we firstly
considered clinical and methodological heterogeneity: that is the
degree to which the included studies varied in terms of partici-
pant, intervention, outcome and characteristics such as length of
follow-up. This assessment of clinical and methodological het-
erogeneity was supplemented by information regarding statistical
heterogeneity - assessed using the Chi² test (a significance level of
P < 0.10 was considered to indicate statistically significant hetero-
geneity) in conjunction with the I² measure (Higgins 2003). I²
examines the percentage of total variation across RCTs that is due
to heterogeneity rather than chance (Higgins 2003). It is generally
considered that I² values of 25% or less may mean a low level of
heterogeneity (Higgins 2003), and values of 75% or more indicate
very high heterogeneity (Deeks 2011). Where there was evidence
of high heterogeneity we planned to explore this further where
possible: see Data synthesis.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. Publication
bias is one of a number of possible causes of ’small study effects’,
that is, a tendency for estimates of the intervention effect to be
more beneficial in smaller RCTs. Funnel plots allow a visual as-
sessment of whether small study effects may be present in a meta-
analysis. A funnel plot is a simple scatter plot of the intervention
effect estimates from individual RCTs against some measure of
each trial’s size or precision (Sterne 2011). We planned to present
funnel plots for meta-analyses comprising 10 RCTs or more using
RevMan 5.3 (RevMan 2014).
Data synthesis
Details of included studies were combined in a narrative review
according to type of comparator, possibly by location of/type of
wound and then by outcomes by time period. Where appropriate
and required clinical and methodological heterogeneity were con-
sidered and we anticipated pooling data when studies appeared
appropriately similar in terms of wound type, intervention type,
duration of follow-up and outcome type, thus synthesis is consid-
ered viable.
Our standard approach formeta-analytical analyses was to employ
a random-effects model. Our preference for the more conservative
random effects model is because statistical assessments can miss
potentially important between-study heterogeneity in small sam-
ples, (Kontopantelis 2012).
A fixed effect analyses was only planned when, in the judgement of
the review authors, there was minimal clinical heterogeneity and
this was supported by an X2 value is estimated to be statistically
non-significant and an I2 of 0% (Kontopantelis 2013). In all other
circumstances a random-effects model will be adopted. If relevant
where clinical heterogeneity was thought to be acceptable or of
interest we planned to meta-analyse even when statistical hetero-
geneity is high - attempting to interpret the causes behind this
heterogeneity - use of meta-regression for that purpose would also
be considered (Thompson 1999; Thompson 2002).
Datawere presented using forest plots where possible. For dichoto-
mous outcomes present the summary estimate as a risk ratio (RR)
with 95% CI. Where continuous outcomes were measured in the
same way across studies, we planned to present a pooled mean dif-
ference (MD) with 95% CI; we planned to pool mean difference
(MD) estimates where studies measured the same outcome us-
ing different methods. For time-to-event data, we planned to plot
(and, if appropriate, pool) estimates of hazard ratios and 95% CIs
as presented in the study reports using the generic inverse variance
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method in RevMan 5.3. Where time to healing was analysed as a
continuous measure but it was not clear if all wounds healed, use
of the outcome in the study will be documented but data would
not be summarised or used in any meta-analysis.
Pooled estimates of treatment effect would be obtained using
Cochrane RevMan software (version 5.3) (RevMan 2014).
’Summary of findings’ tables
We planned to present the main results of the review in ’Summary
of findings’ tables. These tables are used to present key informa-
tion concerning the quality of the evidence, the magnitude of the
effects of the interventions examined, and the sum of the available
data for the main outcomes (Schunemann 2011a). ’Summary of
findings’ tables also include an overall grading of the evidence re-
lated to each of the main outcomes using the GRADE (Grades
of Recommendation, Assessment, Development and Evaluation)
approach. The GRADE approach defines the quality of a body of
evidence as the extent to which one can be confident that an esti-
mate of effect or association is close to the true quantity of specific
interest. The quality of a body of evidence involves consideration
of within-trial risk of bias (methodological quality), directness of
evidence, heterogeneity, precision (or imprecision) of effect esti-
mates and risk of publication bias (Schunemann 2011b).
• time to complete wound healing where analysed using
appropriate survival analysis methods;
• proportion of wounds completely healing during the trial
period;
• adverse events.
Where datawere not pooled itwas decided to conduct theGRADE
assessment for each comparison and present this narratively within
the results section without the presentation of separate summary
of finding tables.
Subgroup analysis and investigation of heterogeneity
Had there been sufficient included trials and data, we had planned
to assess potential heterogeneity across the following areas where
there was evidence of between-trial heterogeneity. We envisaged
conducting subgroup analyses for:
• category of ulcer;
• features of negative pressure system and/or vacuum cycle
protocol used;
• duration of NPWT treatment.
• methodological features of studies (allocation adequately
concealed versus not reported or inadequate) and type of
randomisation (truly randomised with adequate method of
generating the randomisation sequence versus not reported).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies
Results of the search
We screened 75 citations obtained from the electronic search. We
obtained full texts for a further seven studies following their iden-
tification from bibliographic searches. In total we obtained (or at-
tempted to obtain) 22 references, relating to 19 studies, as full-
texts. (Figure 1).
We included four studies in the review (Ashby 2012; de Laat 2011;
Ford 2002; Niezgoda 2004); we excluded 12 studies and three
are awaiting assessment as we have been unable to obtain the full
texts for two (Pruksapong 2011; Yu 2012), and one study did not
have obvious outcome data, but the graphs presented require more
exploration for the data on change in wound volume at two weeks
(Wanner 2003).
Included studies
This review contains four studies (Ashby 2012; de Laat 2011;
Ford 2002; Niezgoda 2004), which collectively contained 149
participants with pressure ulcers. Ulcers were category III and IV
in three studies, Ashby 2012; Ford 2002; Niezgoda 2004, and
category IV only in de Laat 2011.
Two studies were undertaken in the USA (Ford 2002; Niezgoda
2004), one in the UK (Ashby 2012), and one in the Netherlands
(de Laat 2011). From the information available it seems that three
studies used a NPWT machine from the same manufacturer (
Ashby 2012; de Laat 2011; Ford 2002); it was not clear what type
of NPWTmachine was used in the fourth study (Niezgoda 2004).
NPWT was compared with:
• a choice of three standard dressing types in Ashby 2012,
follow-up time 24 weeks: “Devices were used in accordance with
the manufacturer’s guidance. The duration of treatment was
determined by the nurse treating the patient and also the patient,
in accordance with current practice.”
• a wet-to-moist dressing with a sodium hypochlorite 0.25%
solution in de Laat 2011, follow-up time six weeks: “The fluid
connection system was changed at least once a week. Negative
pressure mode of 125 mm Hg.”
• the Healthpoint system (which uses three gel treatments) in
Ford 2002, follow-up time unclear: “NPWT dressings were
changed Mondays, Wednesdays, and Fridays (manufacturer
recommends dressing changes every 48 hours).”
• and to moist wound healing with no further definition in
Niezgoda 2004, follow-up time 6 weeks: no further details.
Ashby 2012 was described as a pilot study. Niezgoda 2004 was
presented as an interim analysis; no further data were available
from the study authors, who confirmed that the study had not
been published in full.
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Excluded studies
Twelve studies were excluded from the review for the following
reasons:
• not a randomised controlled trial (two studies; Mullner
1997; Tauro 2007);
• NPWT was not the only systematic difference between
study groups (two studies; Wagstaff 2014; Zhang 2012);
• no outcomes relevant to this review reported or obtained
from study authors to date (one study; Wild 2008);
• study population had mixed wounds and data on the
treatment of pressure ulcers were not available separately (five
studies; Braakenburg 2006; Hu 2009; Joseph 2000; Mody 2008;
Rahmanian Schwarz 2012);
• study population was not relevant (one study; Moues 2007);
• we were unable to obtain any further information regarding
the study (no abstract or publication; one study; Greer 1999).
Risk of bias in included studies
See Figure 2; Figure 3
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
We deemed Ashby 2012 to be at low risk of selection bias. The
randomisation sequence for the study was computer-generated
and allocation was undertaken via telephone by an operator who
was not directly associated with the trial. The remaining three
studies were classed as being at an unclear risk of selection bias as
they reported limited information about the methods employed.
Blinding
We deemed two studies to be at a low risk of detection bias for
wound healing as they undertook blinded outcome assessment (
Ashby 2012; Ford 2002). It was noted in de Laat 2011 that blinded
outcome assessment was not possible for healing outcomes, so we
classed this study as being at a high risk of detection bias. Niezgoda
2004 did not report any information about blinding being used in
the study, and we classed it as being at an unclear risk of detection
bias.
Incomplete outcome data
We classed two studies as being at low risk of attrition bias (Ashby
2012; de Laat 2011), and two studies at high risk of attrition bias
(Ford 2002; Niezgoda 2004). Ford 2002 enrolled 28 participants
with 41 wounds; 22 participants with 35 wounds completed the
study.Niezgoda 2004 seemed tohave presented an interim analysis
both in terms of only some participants having been randomised
and not all participants having completed follow-up.
Selective reporting
We classed all the studies as being at low risk of reporting bias
except for Niezgoda 2004, which we classed as being at unclear
risk due to the limited information available about it.
Other potential sources of bias
We classed one study as being at high risk of bias due to unit of
analysis issues (Ford 2002). In the de Laat 2011 study participants
could also have more than one ulcer - it was not clear how these
data were analysed and whether there were unit of analyses issues,
so we classed the study as being at unclear risk of bias for this
domain.
Effects of interventions
See Table 1 for a summary of included studies and outcome data.
Comparison 1: NPWT compared with standard
dressings; short-term follow-up (one study, 12
participants)
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One study with 6 weeks follow-up compared NPWT with con-
ventional dressings in people with spinal cord injury and pressure
ulcers (de Laat 2011). The study was deemed to be at high risk of
detection bias.
Primary outcomes
The de Laat 2011 study did not report on complete wound healing
or adverse events.
Secondary outcome: change in ulcer size
There was no evidence of a difference between groups in the num-
ber of pressure ulcers considered to have a 50% (or more) reduc-
tion in wound volume at the end of the six-week follow-up with
83% (5/6) participants recorded as reaching this end point in each
group (RR 1.00, 95% CI 0.60 to 1.66; Analysis 1.1).
The study reported a median time to reach a 50% (or greater)
reduction in wound volume of two weeks (inter-quartile range
(IQR) 1 to 2) in the NPWT-treated group compared with three
weeks (IQR 3 to 4) in the dressing-treated group. We have not
analysed the data further here.GRADE assessment: Very low quality
evidence due to risk of bias, indirectness of the outcome (complete
healing is preferable) and imprecision.
Other secondary outcomes
The de Laat 2011 study did not report on: health-related quality
of life; wound infection; pain; resource use; cost; or wound recur-
rence.
Summary: NPWT compared with standard dressings; short-
term follow-up (one study, 12 participants)
Limited data from one study with 12 participants report no ev-
idence of a difference in numbers achieving a 50% reduction in
wound volume over 6 weeks of follow-up. Using the GRADE ap-
proach this was judged as very low quality evidence due to risk of
bias, indirectness of the outcome and imprecision
Comparison 2: NPWT compared with standard
dressings therapy; medium-term follow-up (one
study, 12 participants)
One study compared NPWT with standard dressings with 24
weeks follow-up (Ashby 2012). The study was a pilot study which
explicitly stated that it was not designed or powered to detect
treatment effects. We judged the study as being at low risk of
bias for all domains. The study compared NPWT with standard
dressings (alginate, foam or hydrofibre - the choice of these being
left to health professionals).
Primary outcome: proportion of wounds healed
There was no evidence of a difference in the number of wounds
healed in the NPWT group (17%, 1/6) and the dressing group
(0%, 0/6): RR 3.00, 95% CI 0.15 to 61.74; Analysis 2.1). The
studywas not powered to detect a difference inwound healing, and
there was such huge imprecision around the estimates that neither
a positive nor negative effect of NPWT can be ruled out.GRADE
assessment: Very low quality evidence due to imprecision.
Primary outcome: adverse events
There was no evidence of a difference in the number of partic-
ipants with adverse events in the NPWTgroup (83%, 4/6) and
the dressing group (67%, 4/6): RR: 1.25, 95% CI 0.64 to 2.44;
Analysis 2.2). Again the study was underpowered and findings
were imprecise largely as it was not designed to assess relative treat-
ment effects. GRADE assessment: Very low quality evidence due to
imprecision.
Secondary outcomes
The Ashby 2012 study did not report on: change in ulcer size,
health-related quality of life, wound infection, pain, resource use,
cost, or wound recurrence. It did report on the number of trial
treatment visits that were made, but we did not extract these data
as the duration of treatments differed (Table 1).
Summary: NPWT compared with standard dressings
therapy; medium-term follow-up (one study, 12 participants)
Limited evidence from a study with 12 participants reported no
evidence of a difference between groups for ulcer healing or adverse
events. The study was underpowered and its finds are far from
conclusive. GRADE assessment: Very low quality evidence due to
imprecision.
Comparison 3: NPWT compared with moist wound
healing; short-term follow-up (one study, 97
participants)
One study compared NPWT with ’moist wound healing’, but
provided few details about the comparator intervention (Niezgoda
2004). The only information available came from a conference ab-
stract; no further published information was available. The study
was presented as an interim analysis at a point when recruitment
and follow-up of recruited participants was not complete.We con-
sidered it to be at a high risk of attrition bias.
Primary outcomes
The Niezgoda 2004 study did not report on complete wound
healing or adverse events.
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Secondary outcome: change in ulcer size
The Niezgoda 2004 study reported only unadjusted data for
change in ulcer size (Table 1) which we did not consider further
as per our methods.
Secondary outcome: resource use
The mean cost of care (including materials, labour, debridements
and length of stay) in the NPWT-treated group was USD 130
compared with USD 132 in the moist wound healing group. No
information about the variation around these estimates was pre-
sented and the data are not analysed further here.
Other secondary outcomes
TheNiezgoda 2004 study did not report on: health-related quality
of life, wound infection, pain, cost, or wound recurrence.
Summary: NPWT compared with moist wound healing;
short-term follow-up (one study, 97 participants)
The only study to compare NPWT with moist wound healing
provided very limited information fromwhich it is not possible to
draw conclusions regarding the effectiveness of NPWT with this
alternative pressure ulcer treatment regime. There was not enough
data to conduct a GRADE assessment but the lack of data meant
we consider this very low quality evidence.
Comparison 4: NPWT compared with the
Healthpoint system (one study, 28 participants)
One study compared NPWT with the Healthpoint system (Ford
2002). The Healthpoint System consists of three gel products:
Accuzyme®, Iodosorb®, and Panafil®. The study reports that
of the choice of three treatments available - participants whose
wounds showed substantial exudate received Iodosorb® or Iod-
oflex®; those patients whose ulcers were clean and granulating
received Panafil®. Accuzyme® was not used.We considered the
study to be at high risk of attrition bias; it also had unit of analysis
issues. It should be noted that the study was reported to be an
interim analysis, and that the length of follow-up was unclear.
Primary outcome data: proportion of ulcers healed
The study reported that two ulcers healed in each study arm.
However whilst the number of participants for the study were
reported (n = 28), the number in each arm was not, and there
were 41 wounds in the study. It was not clear whether one or two
participants healed in each group. Due to these unit of analysis
issues, we have not analysed the data further here.
Primary outcome data: adverse events
The Ford 2002 study did not report adverse events clearly (Table
1).
Secondary outcomes
The Ford 2002 study did not report on change in ulcer size, health-
related quality of life, wound infection, pain, resource use, cost,
or wound recurrence.
Summary: NPWT compared with the Healthpoint system
(1 study, 28 participants)
Very few data were available from comparison of NPWT with
the Healthpoint system. We are unable to make any conclusions
regarding the effectiveness of NPWT compared with the Health-
point system. There was not enough data to conduct a GRADE
assessment but the lack of data meant we consider this very low qual-
ity evidence.
D I S C U S S I O N
Summary of main results
We included a total of four studies in this review (Ashby 2012; de
Laat 2011; Ford 2002; Niezgoda 2004). Only Ashby 2012, which
was a pilot/feasibility study, reported primary outcome data on
both the proportion of wounds healed and adverse events that we
report fully in the review. Whilst there was no evidence of a differ-
ence between NPWT and standard dressings for these outcomes,
the study was hugely underpowered having only 12 participants
and so its estimates were very imprecise and inconclusive. The fact
that only one participant healed during the 24-week follow-up
period highlights the need for adequate follow-up in studies that
evaluate treatments for severe pressure ulcers.
We classed the three remaining studies as being at high risk of bias
for at least one risk of bias domain (de Laat 2011; Ford 2002;
Niezgoda 2004); they also had short or unclear follow-up times.
One of these studies that also had 12 participants (de Laat 2011),
reported no evidence of a difference in the number of wounds
achieving a 50% (or greater) reduction in wound volume over a
six-week follow-up period. This was a surrogate outcome and the
comparison was again underpowered and imprecise.
Overall there is low quality and inconclusive evidence regarding
the clinical effectiveness of NPWT as a treatment for pressure
ulcers.
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Quality of the evidence
RCTs need to be adequately powered so that they are able to detect
treatment effects of a specified size, should they exist. This means
that sample size calculations should be used to help estimate the
number of people recruited to a trial. Additionally, trials should
have adequate an follow-up period so that there is enough time in
which important outcome events, such as complete wound heal-
ing, can occur. The trials included in this review were all small
and their follow-up periods were also generally short, and in one
case was not reported clearly. This results in a limited evidence
base: further problems in quality also stem from the limited out-
comes reported in the trials. Wound healing or preparation for
closure surgery, as well as adverse events, are potentially important
outcomes. Such outcomes should be collected rigorously using a
clear methodology. On this occasion there was a limited number
of studies that could be included in this review; those studies pre-
sented limited outcome data with estimates that were imprecise
and had wide confidence intervals.
Rigorous RCTs in wound care are feasible - they must follow good
practice conduct and reporting guidelines, for example CON-
SORT (Schulz 2010). Key areas of good practice are the robust
generation of a randomisation sequence, for example, a computer-
generated one; robust allocation concealment, for example the use
of a telephone randomisation service; and use of blinded outcome
assessment where possible. All this information should be stated
clearly in the study report, as trial authors should anticipate the
inclusion of their trials in systematic reviews. Additionally, studies
should report clearly how they planned to collect adverse event
data and how this process was standardised for both treatment
arms. In terms of analysis, where possible, data from all partic-
ipants should be included - that is an intention-to-treat analy-
sis should be conducted - and measures of variation such as the
standard deviation or standard error should be presented around
measures where appropriate. Steps should be taken while a trial is
being conducted to prevent the occurrence of missing data as far
as is possible.
Potential biases in the review process
The review considered as much evidence as it was possible to ob-
tain, including studies that were not published in English-lan-
guage journals. It is possible that there may be unpublished data
that we have not been able to access and there is a potential for
publication bias, however, this is likely to be a limited issue in this
review.
Agreements and disagreements with other
studies or reviews
NICE guidelines currently state, “Do not routinely offer adults
negative pressure wound therapy to treat a pressure ulcer, unless it
is necessary to reduce the number of dressing changes (for example,
in a wound with a large amount of exudate)” (NICE 2014). The
review underpinning this NICE guidance is based is similar to our
review, although we included one additional RCT. Our review did
not find or report any cost-effectiveness data reported as part of the
RCT data. However, two published cost-effectiveness modelling
studies (one conducted as part of the NICE guidelines; NICE
2014) draw on available data, and emphasise again the uncertainty
around the clinical and cost-effectiveness of NPWT as a treatment
for pressure ulcers.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This comprehensive review of current randomised controlled trial
evidence has highlighted the current uncertainty regarding the ef-
fectiveness of negative pressure wound therapy (NPWT) as a treat-
ment for pressure ulcers. Given the current uncertainties, when
choosing between alternative treatment options for pressure ulcers,
practitioners may elect to consider characteristics such as costs and
symptom management properties.
Implications for research
Where it is a priority for patients, carers and health professionals,
further research to evaluate the clinical and cost effectiveness of
NPWT as a treatment for pressure ulcers is warranted. Large and
robust randomised controlled trials would probably be the most
appropriate study design.
When trials are conducted, good practice guidelines must be fol-
lowed in their design, implementation and reporting. Further re-
views are being conducted to synthesise evidence regarding the
effect of other treatments for pressure ulcers. It would then be
useful to conduct further evidence synthesis (overviews of reviews,
network meta-analysis or both) to aid decision-making about the
choice of treatments for pressure ulcers across all treatment op-
tions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ashby 2012
Methods 2-arm RCT
Conducted in home and hospital settings in 1 geographical location in the UK
Duration of follow-up was a maximum of 24 weeks
Participants 12 participants: all included in analysis
Inclusion criteria listed: pressure ulcer graded III or IV according to the EuropeanPressure
Ulcer Advisory Panel Grading System; must receive primary care via Leeds Primary Care
Trust; ulcer should contain at least 80% viable tissue or have a very thin layer of slough
(nonviable tissue) requiring no further debridement prior to use of NPWT
Exclusion criteria listed: presence of unclear undermining in the pressure ulcer cavity
precluding the use of NPWT; pressure ulcer with necrotic tissue, eschar or necrotic
bone present; patient has limited life expectancy; pressure ulcer located where, in the
opinion of the treating clinician, a vacuum seal could not be obtained; pressure ulcer
too close to exposed blood vessels or organs, or both, anastomotic sites or nerves, or
both; patient unable to give valid informed consent because of incapacity; patient was
unable to consent as trial materials were not available in a suitable language; patient did
not wish to consent to participation within trial; a clinical judgement was made that
the patient was not receiving adequate nutrition to allow treatment with NPWT; other
reasons, in the clinical judgement of the treating clinician or nurse, which excluded the
patient from the trial
Interventions Group A: NPWT (VAC Therapy Units and Systems range, manufactured by Kinetic
Concepts Inc (KCI; San Antonio, TX, USA; n = 6). “Devices were used in accordance
with the manufacturer’s guidance. The duration of treatment was determined by the
nurse treating the patient and also the patient, in accordance with current practice.”
Group B: standard care (n = 6). “One of the following, chosen by the treating nurse: a
spun hydrocolloid (fibrous hydrocolloid) dressing, a foam dressing or an alginate dressing
(all non-silver). The frequency of dressing changes was determined by the nurse (standard
practice).”
Co-interventions: none described
Outcomes Primary outcomes: complete wound healing (% ulcers healed)
Secondary outcomes: adverse events
Notes Pilot study
Only one ulcer per participant was followed
Duration of follow-up differed between groups: mean duration was 3.8 months for
Group A and 5.0 months for Group B
Risk of bias
Bias Authors’ judgement Support for judgement
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Ashby 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomisationwas conducted us-
ingpre-generated randompermuted blocks
(block sizes of four and six). A data man-
ager at the York Trials Unit, who was com-
pletely independent of the research team,
created the randomisation programme”
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “the research nurse telephoned a se-
cure and remote randomisation service, lo-
cated at the York Trials Unit (University of
York, UK).”
Comment: central allocation was used to
conceal allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Wound healing
Quote: “We piloted a blinded outcome as-
sessment process using digital photographs
of the wound taken using the mobile cam-
era phone”
Comment: blinding of key study personnel
used and unlikely that the blinding could
have been broken
Adverse events
Comment: not blinded
Resource use
Comment: not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: flow chart shows that all partic-
ipant data were included in analysis
Selective reporting (reporting bias) Low risk Comment: outcomes identified in the
methods section were reported in the re-
sults (and were outcomes that would be ex-
pected to be included in such a study). Pro-
tocol not seen. Only 1 participant’s pres-
sure ulcer healed so not possible to calcu-
late mean ’time to healing’
Other bias Unclear risk No unit of analyses issues
Quote: “Whilst the research nurse was pri-
marily responsible for data collection, this
responsibility was also delegated to nurses
treating patients in acute and community
settings.”
Comment: there may have been incon-
sistency in reporting between community
nurses
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de Laat 2011
Methods 2-arm RCT
Multi-centred, conducted in hospital settings in the Netherlands
Duration of follow-up was a maximum of 6 weeks
Participants 24 participants (with a total of 28 wounds). 12 of these participants had pressure ulcers.
Data were extracted and presented for the pressure ulcer sub-group only
Inclusion criteria listed: patients ≥ 18 years who were admitted to the study hospitals
with difficult-to-heal surgical wounds, or paraplegic and tetraplegic patients with pressure
ulcers grade IV according to the European Pressure Ulcer Advisory Panel grading system
Exclusion criteria listed: patientswith bleedingdisorders; thrombolytic treatment; fistulas
to organs or body cavities; malignant disease; untreated osteomyelitis; life expectancy of
< 1 year; radiation or chemical exposure; pregnant or lactating women; people unable
to comply with 1 of the interventions or who had been treated with 1 of the study
treatments in the past 30 days
Interventions Group A: NPWT (VAC system, vacuum-assisted closure; KCI, San Antonio, TX, USA;
n = 6, 7 pressure ulcers). “Devices were used in accordance with the manufacturer’s
guidance. The foam dressings and the TRAC Pad were changed 3 times a week (Monday
morning, and Wednesday and Friday in the afternoon). The fluid connection system
was changed at least once a week. Negative pressure mode of 125 mm Hg.”
Group B: conventional dressing therapy (n = 6, 9 pressure ulcers) with a sodium
hypochlorite 0.25% solution. “This wet-to-moist dressing was changed 2 to 3 times a
day, depending on the wound debris. The sodium hypochlorite solution was prepared
by one hospital pharmacist.”
Co-intervention: wound debridement took place when considered clinically necessary
before the start of the therapy and during treatment. Participants received (medical) care
as needed
Outcomes Primary outcomes: adverse events
Secondary outcomes: change in wound size
Notes Some participants had more than one ulcer, so there was potential for unit of analysis
issues although this is not clear from the report
Funding source: the surgical department of Nijmegen University Medical Centre
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “A prospective stratified random-
ized controlled trial was carried out …”
Comment: method of generating of ran-
dom schedule not reported
Allocation concealment (selection bias) Unclear risk Quote: “Patients in the difficult-to-heal
surgical wounds group or the spinal cord
injury patients with pressure ulcer group,
were both allocated randomly to either
the topical negative pressure group or the
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de Laat 2011 (Continued)
sodium hypochlorite group by using sealed
envelopes.”
Comment: whilst sealed envelopes were
used to conceal allocation it is not clear
whether these were numbered to ensure se-
quential opening, or opened by an inde-
pendent person
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The median treatment time to 50% re-
duction of wound volume
Quote: “Because of the striking foam im-
prints in the wound of patients with topical
negative pressure therapy blinding was not
possible.”
Comment: not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: flow chart shows that all partic-
ipant and all wounds data were included in
analysis; the presentation of the data and
methods outlined show that an ITT anal-
ysis was done considering all randomised
participants
Selective reporting (reporting bias) Low risk Comment: based on paper only, protocol
not obtained
Other bias Low risk Comment: it was not clear whether there
were unit of analyses issues
Ford 2002
Methods 2-arm RCT
Single-centred, conducted in hospital settings at Boston Medical in the USA
Duration of follow-up unclear - stated as ranging from 3 to 10 months not clear if it
different between trial groups
Participants 28 participants with 41 wounds enrolled: stated that 22 participants with 35 wounds
completed the study
Inclusion criteria listed: presence of stage III or IV ulcer for ≥ 4 weeks; albumin ≥ 2.0;
age 21-80 years; ulcer volume after debridement = 10 ml-150 ml
Exclusion criteria listed: fistulas to organs or body cavities; malignancy in the wound;
pregnant or lactating women; Hashimoto thyroiditis; Graves’ disease; iodine allergy; sys-
temic sepsis; electrical burns; radiation exposure; chemical exposure; cancer; connective
tissue disease; chronic renal or pulmonary disease; uncontrolled diabetes; corticosteroids
or immunosuppressive agents; cardiac pacemaker; ferromagnetic clamps; recent place-
ment of orthopaedic hardware
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Ford 2002 (Continued)
Interventions Group A: NPWT (number of participants in trial group not reported; n = 20 ulcers).
Report suggests used theKCIVACproduct.Duration of treatmentwas 6weeks. “NPWT
dressings were changed Mondays, Wednesdays, and Fridays (manufacturer recommends
dressing changes every 48 hours).”
Group B: Healthpoint System (which consists of three gel products: Accuzyme®, Io-
dosorb®, and Panafil®). The study reports that of the choice of three treatments avail-
able - participants whose wounds showed substantial exudate received Iodosorb® or
Iodoflex®; those patients whose ulcers were clean and granulating received Panafil®.
Because all wounds were debrided surgically as appropriate, Accuzyme® was not used.
The number of participants in the trial groups was not reported; n = 15 ulcers. Duration
of treatment was 6 weeks. “HP [Healthpoint] dressings were changed once or twice daily,
depending on the degree of wound drainage.”
Outcomes Primary outcomes:
Complete wound healing (% ulcers healed)
Adverse events
Secondary outcomes: not reported
Notes Some participants had more than one ulcers: potential unit of analysis issue
Funding source: the Plastic Surgery Education Foundation and Kinetic Concepts, San
Antonio, TX
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients underwent ulcer debride-
ment as necessary, followed by random as-
signment to 6 weeks of treatment with ei-
ther VAC or HP. Randomization was based
on a table of random letters, V or H, gen-
erated before the trial began.”
Comment: method of generation of ran-
dom schedule not clear
Allocation concealment (selection bias) Unclear risk Comment: method of allocation not re-
ported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Wound healing
Quote: “Blinded clinic staff, including
nurses, medical students, and interns, mea-
sured wounds and obtained plaster impres-
sions.”
Comment: blinding of key study personnel
used
Adverse events
Comment: not blinded
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Ford 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “28 participants with 41 wounds
were enrolled; 22 participants with 35
wounds completed the study.”
Comment: report suggest 6 participants
with 1 wound each were lost to follow-up.
It is not clear which trial group these par-
ticipants were from. The paper also reports
that the average patient age was 41.7 years
in Group A and 54.4 years in Group B. It
is not clear if this was before or after the
loss of 6 participants, but there seems to be
imbalance
Selective reporting (reporting bias) Low risk Comment: based on paper only, protocol
not obtained
Other bias High risk Comment: possible unit of analysis issue
due to participants with multiple wounds
in the trial with data being reported at the
wound rather than participant level.No in-
formation on the number of participants
randomised to each group
Duration of follow-up and any differences
in trial groups of follow-up times were not
clear
Niezgoda 2004
Methods 2-arm RCT
Conducted in USA
Follow-up (at time results presented) 42 days (6 weeks)
Participants 97 participants.
Inclusion criteria listed: stage III and IV pressure ulcers located on the trunk or trochanter
regions
Exclusion criteria listed: none listed
Interventions Group A: NPWT (VAC) n = 54
Group B: moist wound healing (no further information) n = 43
Outcomes Primary outcomes: none
Secondary outcomes:
Change in ulcer size (unadjusted)
Cost
Notes Conference abstract; interim analyses; abstract notes that full follow-up was planned as
82 days
Authors contacted via e-mail and confirmed that the full study was not published and
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Niezgoda 2004 (Continued)
that outcome data were not available to us
Funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk No information
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
High risk Interim analysis in terms of both partici-
pant numbers and length of follow-up for
those participants recruited
Selective reporting (reporting bias) Unclear risk No information
Other bias Unclear risk No information; interim analysis - not clear
why further work not available
Abbreviations
HP: Health point
KCI: Kinetic Concepts Inc
NPWT: negative pressure wound therapy
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Braakenburg 2006 Study population had range of wounds - authors contacted to try and obtain pressure ulcer data
Greer 1999 Unable to locate an abstract or full text publication
Hu 2009 Study population had range of wounds - based on translation
Joseph 2000 Study population had range of wounds - authors contacted to try and obtain pressure ulcer data
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(Continued)
Mody 2008 Study population had range of wound wounds - authors contacted to try and obtain pressure ulcer data.
11/48 wounds were pressure ulcers, but it seems that only 2 were in the NPWT group
Moues 2007 Not corrected study population. Confirmed by study author
Mullner 1997 Not an RCT
Rahmanian Schwarz 2012 Study population had range of wound - authors contacted to try and obtain pressure ulcer data
Tauro 2007 Not an RCT
Wagstaff 2014 NPWT was not the only systematic difference between groups: the trial applied NPWT in both com-
parison groups
Wild 2008 No relevant outcome data reported - authors contacted. RCT contained 10 participants in total
Zhang 2012 NPWT was not the only systematic difference between groups: the trial applied NPWT in both com-
parison groups
Abbreviations
NPWT: negative pressure wound therapy
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Pruksapong 2011
Methods States is RCT
Participants People with chronic wounds
Interventions Portable vacuum dressing
Outcomes
Notes Unable to obtain paper to date. Abstract notes that 30 participants with chronic wounds were recruited and describes
the intervention as a vacuum dressing. It is possible that these wounds are pressure ulcers and that the treatment is
NPWT. This need to be confirmed using the full text which we have been unable to obtain to date
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Wanner 2003
Methods Describes that participants were randomly put into groups - no further detail
Participants People with pressure ulcers
Interventions NPWT
Outcomes Time to 50% reduction in wound area
Notes The outcome data is unclear we have contacted the authors to ask for more information
Yu 2012
Methods Described as RCT in title
Participants People with pressure ulcers
Interventions NPWT
Outcomes
Notes Unable to obtain this conference abstract or any associated publication to date
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D A T A A N D A N A L Y S E S
Comparison 1. NPWT compared with standard dressings: short-term follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers with 50%
or greater reduction in wound
area
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. NPWT compared with standard dressings: medium-term follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of wounds healed 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 NPWT compared with standard dressings: short-term follow-up, Outcome 1
Proportion of ulcers with 50% or greater reduction in wound area.
Review: Negative pressure wound therapy for treating pressure ulcers
Comparison: 1 NPWT compared with standard dressings: short-term follow-up
Outcome: 1 Proportion of ulcers with 50% or greater reduction in wound area
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
de Laat 2011 5/6 5/6 1.00 [ 0.60, 1.66 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (NPWT), 5 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NPWT Favours dressing
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Analysis 2.1. Comparison 2 NPWT compared with standard dressings: medium-term follow-up, Outcome 1
Proportion of wounds healed.
Review: Negative pressure wound therapy for treating pressure ulcers
Comparison: 2 NPWT compared with standard dressings: medium-term follow-up
Outcome: 1 Proportion of wounds healed
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashby 2012 1/6 0/6 3.00 [ 0.15, 61.74 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (NPWT), 0 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours dressings Favours NPWT
Analysis 2.2. Comparison 2 NPWT compared with standard dressings: medium-term follow-up, Outcome 2
Adverse events.
Review: Negative pressure wound therapy for treating pressure ulcers
Comparison: 2 NPWT compared with standard dressings: medium-term follow-up
Outcome: 2 Adverse events
Study or subgroup NPWT Dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ashby 2012 5/6 4/6 1.25 [ 0.64, 2.44 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (NPWT), 4 (Dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours dressings Favours NPWT
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A D D I T I O N A L T A B L E S
Table 1. Study outcomes
Study Com-
parison
Length
of fol-
low-up
Time
points
of data
pre-
sented
Time
to heal-
ing
data
% Ul-
cer
healed
Ad-
verse
events
Change
in ulcer
size
Health-
related
quality
of life
Wound
infec-
tion
and
pain
Re-
source
use
Cost Wound
recur-
rence
Ashby
2012
Group
A:
NPWT
(n = 6)
Group
B:
stan-
dard
dress-
ings (n
= 6)
“One of
the fol-
lowing,
chosen
by the
treating
nurse:
a spun
hydro-
colloid
(fibrous
hydro-
colloid)
dress-
ing, a
foam
dress-
ing
or an
alginate
dress-
ing (all
non-
silver)”
24
weeks
24
weeks
Not re-
ported
Group
A: 1/6
Group
B: 0/6
Num-
ber of
partici-
pants
with an
AE:
Group
A: 5/6
Group
B: 4/6
Seri-
ous AE
(num-
ber of
events)
:
Group
A: 4
Group
B: 4
Non-
seri-
ous AE
(num-
ber of
events)
:
Group
A: 12
Group
B: 8
Not re-
ported
Not re-
ported
Not re-
ported
Num-
ber of
trial
treat-
ment
visits
re-
ported
but
not ex-
tracted
as the
dura-
tion of
treat-
ments
were
differ-
ent
Not re-
ported
Not re-
ported
de Laat
2011
Group
A:
NPWT
(n = 6; 9
ulcers)
Group
6 weeks 6 weeks Not re-
ported
Not re-
ported
Not re-
ported
for PU
group
sepa-
Num-
ber
with
50%
(or
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
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Table 1. Study outcomes (Continued)
B: con-
ven-
tional
dress-
ing
therapy
(n = 6; 7
ulcers)
rately greater)
reduc-
tion in
wound
size:
Group
A: 5/6
Group
B: 5/6
Me-
dian
treat-
ment
time in
weeks
un-
til 50%
wound
volume
reduc-
tion
(IQR):
Group
A: 2 (1-
2)
Group
B: 3 (3-
4)
Ford
2002
Group
A:
NPWT
Group
B:
Health-
point
system
Total of
28 par-
tic-
ipants -
num-
ber allo-
cated to
each
group
was
not pre-
sented
3-10
months
Not
clear
what
time
point
out-
comes
were
pre-
sented
for
Not re-
ported
Group
A:
2 ulcers
healed
Group
B:
2 ulcers
healed
Not re-
ported
clearly:
1 lateral
malleo-
lar ulcer
compli-
cated
by sep-
sis, re-
quiring
ampu-
tation
Data
re-
ported
on
Mean
%
reduc-
tion in
volume
could
not be
used
as it
was not
clear if
some
partic-
ipants
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
Not re-
ported
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Table 1. Study outcomes (Continued)
had
data
consid-
ered in
both
trial
groups
Niez-
goda
2004
Group
A:
NPWT
(n = 54)
Group
B:
moist
wound
healing
(no fur-
ther de-
tails) (n
= 43)
42 days 42 days Not re-
ported
Not re-
ported
Not re-
ported
Unad-
justed
Re-
ported
that
wounds
in
Group
A had
had a
mean
reduc-
tion in
of 12.
7cm²
(stan-
dard
devia-
tion 93.
7)
Wounds
in
Group
B had
had a
mean
increase
in area
of 23.
5cm²
(stan-
dard
devi-
ation
261.
2cm²)
Not re-
ported
Not re-
ported
Not re-
ported
Mean
cost of
care per
day (in-
cluded
materi-
als,
labour,
de-
bride-
ments,
and
length
of stay):
Group
A:USD
130
Group
B:USD
132
No
stan-
dard
devia-
tions re-
ported
Not re-
ported
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Abbreviations
AE: adverse event(s)
IQR: inter-quartile range
PU: pressure ulcer to here
A P P E N D I C E S
Appendix 1. Search strategies
Ovid MEDLINE(R) <1946 to July Week 2 2014>
--------------------------------------------------------------------------------
1 exp Negative-Pressure Wound Therapy/
2 exp Suction/
3 exp Vacuum/
4 (negative pressure or negative-pressure or TNP or NPWT).tw.
5 (sub-atmospheric or subatmospheric).tw.
6 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
7 (wound adj2 suction*).tw.
8 (wound adj5 drainage).tw.
9 ((foam adj suction) or (suction adj dressing*)).tw.
10 (vacuum assisted closure technique or VAC).tw.
11 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj closure) or (vacuum adj compression) or
(vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage)).tw.
12 or/1-11
13 exp Pressure Ulcer/
14 (pressure adj (ulcer* or sore* or injur*)).tw.
15 (decubitus adj (ulcer* or sore*)).tw.
16 (bedsore* or bed sore*).tw.
17 or/13-16
18 12 and 17
19 randomized controlled trial.pt.
20 controlled clinical trial.pt.
21 randomi?ed.ab.
22 placebo.ab.
23 clinical trials as topic.sh.
24 randomly.ab.
25 trial.ti.
26 exp animals/ not humans.sh.
27 18 and 26
EMBASE <1974 to 2014 July 21>
--------------------------------------------------------------------------------
1 exp Suction drainage/
2 exp Vacuum assisted closure/
3 (negative pressure or negative-pressure or TNP or NPWT).tw.
4 (sub-atmospheric or subatmospheric).tw.
5 ((seal$ adj surface$) or (seal$ adj aspirat$)).tw.
6 (wound adj2 suction$).tw.
7 (wound adj5 drainage).tw.
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8 ((foam adj suction) or (suction adj dressing$)).tw.
9 (vacuum assisted closure technique or VAC).tw.
10 ((vacuum adj therapy) or (vacuum adj dressing$) or (vacuum adj seal$) or (vacuum adj closure) or (vacuum adj compression) or
(vacuum adj pack$) or (vacuum adj drainage) or (suction$ adj drainage)).tw.
11 or/1-10
12 exp decubitus/
13 (pressure adj (ulcer* or sore* or injur*)).tw.
14 (decubitus adj (ulcer* or sore*)).tw.
15 (bedsore* or bed sore*).tw.
16 or/12-15
17 11 and 16
18 Randomized controlled trials/
19 Single-Blind Method/
20 Double-Blind Method/
21 Crossover Procedure/
22 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
23 (doubl$ adj blind$).ti,ab.
24 (singl$ adj blind$).ti,ab.
25 or/18-24
26 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
27 human/ or human cell/
28 and/26-27
29 26 not 28
30 25 not 29
31 17 and 30
CINAHL July 23, 2014
S31 S18 AND S30
S30 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29
S29 MH “Quantitative Studies”
S28 TI placebo* or AB placebo*
S27 MH “Placebos”
S26 TI random* allocat* or AB random* allocat*
S25 MH “Random Assignment”
S24 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S23 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S22 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S21 TI clinic* N1 trial* or AB clinic* N1 trial*
S20 PT Clinical trial
S19 MH “Clinical Trials+”
S18 S12 AND S17
S17 S13 OR S14 OR S15 OR S16
S16 TI decubitus or AB decubitus
S15 TI ( bed sore* or bedsore* ) or AB ( bed sore* or bedsore* )
S14 TI ( pressure ulcer* or pressure sore* ) or AB ( pressure ulcer* or pressure sore* )
S13 (MH “Pressure Ulcer+”)
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TI foam suction or suction dressing* or suction drainage or AB foam suction or suction dressing* or suction drainage
S10 AB vacuum therapy or vacuum dressing* or vacuum seal* or vacuum closure or vacuum compression or vacuum pack or vacuum
drainage
S9 TI vacuum therapy or vacuum dressing* or vacuum seal* or vacuum closure or vacuum compression or vacuum pack or vacuum
drainage
S8 TI wound N5 drainage or AB wound N5 drainage
S7 TI wound N5 suction* or AB wound N5 suction*
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S6 TI seal* N1 surface* or seal* N1 aspirat* or AB seal* N1 surface* or seal* N1 aspirat*
S5 TI sub-atmospheric or subatmospheric or AB sub-atmospheric or subatmospheric
S4 TI negative pressure or negative-pressure or TNP or AB negative pressure or negative-pressure or TNP
S3 (MH “Negative Pressure Wound Therapy”)
S2 (MH “Vacuum”)
S1 (MH “Suction+”)
Appendix 2. ’Risk of bias’ assessment (individually randomised controlled trials)
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of randomnumbers); assignment envelopes were usedwithout appropriate
safeguards (e.g. if envelopes were unsealed or non opaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if themethod of concealment
is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
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3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following.
• Insufficient information available to permit a judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have
a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes was not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ’As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
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Unclear
Either of the following.
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as
an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information available to permit a judgement of low or high risk of bias. It is likely that the majority of studies will fall into
this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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Appendix 3. ’Risk of bias’ assessment (cluster randomised controlled trials)
In cluster-randomised trials, particular biases to consider include:
• recruitment bias;
• baseline imbalance;
• loss of clusters;
• incorrect analysis; and
• comparability with individually randomised trials.
Recruitment bias can occur when individuals are recruited to the trial after the clusters have been randomised, as the knowledge of
whether each cluster is an ’intervention’ or ’control’ cluster could affect the types of participants recruited.
Baseline imbalance: cluster-randomised trials often randomise all clusters at once, so lack of concealment of an allocation sequence
should not usually be an issue. However, because small numbers of clusters are randomised, there is a possibility of chance baseline
imbalance between the randomised groups, in terms of either the clusters or the individuals. Although not a form of bias as such,
the risk of baseline differences can be reduced by using stratified or pair-matched randomisation of clusters. Reporting of the baseline
comparability of clusters, or statistical adjustment for baseline characteristics, can help reduce concern about the effects of baseline
imbalance.
Loss of clusters: occasionally complete clusters are lost from a trial, and have to be omitted from the analysis. Just as for missing
outcome data in individually randomised trials, this may lead to bias. In addition, missing outcomes for individuals within clusters
may also lead to a risk of bias in cluster-randomised trials.
Incorrect analysis: many cluster-randomised trials are analysed by incorrect statistical methods, not taking the clustering into account.
Such analyses create a ’unit of analysis error’ and produce over-precise results (the standard error of the estimated intervention effect is
too small) and P values that are too small. They do not lead to biased estimates of effect. However, if they remain uncorrected, they
will receive too much weight in a meta-analysis.
Comparability with individually randomised trials: in a meta-analysis that includes both cluster and individually randomised trials,
or cluster-randomised trials with different types of clusters, possible differences between the intervention effects being estimated need
to be considered. For example, in a vaccine trial of infectious diseases, a vaccine applied to all individuals in a community would be
expected to be more effective than if the vaccine was applied to only half of the people. Another example is provided by discussion of
a Cochrane review of hip protectors by Hahn 2005, where cluster trials showed a large positive effect whereas individually randomised
trials did not show any clear benefit. One possible explanation for this is that there was a ’herd effect’ in the cluster-randomised trials
(which were often performed in nursing homes, where compliance with using the protectors may have been enhanced). In general, such
’contamination’ would lead to underestimates of effect. Thus, if an intervention effect is still demonstrated, despite contamination in
those trials that were not cluster-randomised, a confident conclusion about the presence of an effect can be drawn. However, the size
of the effect is likely to be underestimated. Contamination and ’herd effects’ may be different for different types of cluster.
WH A T ’ S N E W
Last assessed as up-to-date: 19 May 2015.
Date Event Description
2 June 2015 Amended Acknowledgements completed and updated
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have removed the outcome ’fistula formation’ as it was not thought to be a key adverse event in this patient group. The last sentence
of the assessment of risk of bias of included studies section in the protocol as been amended slightly from:
“We will class studies with an assessment of high risk of bias for the randomisation sequence domain and/or the allocation concealment
domain and/or the blinded outcome assessment domain (for specified outcome) as being at overall high risk of bias (for specified
outcome).”
to:
“We will class studies with an assessment of high risk of bias for the randomisation sequence domain and/or the allocation concealment
domain to be at high risk of selection bias; those at high risk of bias for the blinded outcome assessment domain (for specified outcome)
will be judged as being at a high risk of detection bias and those with a high risk of bias for the intention to treatment domain will be
judged as being at a high risk of attrition bias (for specified outcome).”
We did not produce ’Summary of findings’ tables as the data available were so limited.
Change to unit of analysis wording
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Negative-Pressure Wound Therapy; Bandages; Pressure Ulcer [∗therapy]; Randomized Controlled Trials as Topic; Wound Healing
MeSH check words
Humans
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